◀ Back to BCL6

BCL6 — CDKN1A

Text-mined interactions from Literome

DeHaan et al., Cancer Chemother Pharmacol 2001 : In the ovarian carcinoma cell line A2780, cisplatin was shown to induce expression of p21WAF1, Gadd45 and Mdm2, but cisplatin had no effect on expression of Bax, Bcl-2, Bcl-x1 , or Cyclin G. Inhibition of cisplatin induced ERK activity by PD98059 resulted in decreased levels of p21WAF1 , Gadd45 and Mdm2
Phan et al., Nat Immunol 2005 : BCL6 interacted with the transcriptional activator Miz-1 and, via Miz-1, bound to the promoter and suppressed transcription of the cell cycle arrest gene CDKN1A
Liu et al., Int J Oncol 2009 (Leukemia) : In identifying a molecular mechanism responsible for these effects MCT-1 alone and in combination with AZA induced p15INK4b, p21WAF1/CIP1 and Caspase-3 whilst attenuating Bcl-XL expression
Festuccia et al., Endocr Relat Cancer 2009 (Disease Models, Animal...) : In vivo, azacitidine ( 0.8 mg/kg i.p. ) reduced tumor proliferation and induced apoptosis in both xenografts upmodulating the expression of p16INKA, Bax, Bak, p21/WAF1 , and p27/KIP1, and inhibiting the activation of Akt activity and the expression of cyclin D1, Bcl-2, and Bcl-XL
Gravina et al., Prostate 2010 (Neoplasms, Experimental...) : This combined treatment up-regulated the expression of FasL, phospho-FADD, p16 ( INKA ), Bax, Bak, and p21 ( WAF1 ), and inhibited FLIP, Bcl-2, and Bcl-XL expression
Vincent et al., FEBS Lett 2012 (Breast Neoplasms) : Our studies reveal that NUPR1 confers growth benefit and chemoresistance by causing Akt mediated phosphorylation and subsequent cytoplasmic re-localization of p21 and activation of the anti-apoptotic Bcl-xL protein